Characterisation of auto-antibodies against ADAMTS-13 in patients with a history of TTP.
Completed
- Conditions
- small vessel thrombosis10014523
- Registration Number
- NL-OMON32888
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
Patients with a history of TTP
Exclusion Criteria
<18 years
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The anti ADAMTS-13 antibodies epitopes in patients with a history of TTP</p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the pathogenic role of ADAMTS-13 auto-antibodies in relapsing TTP and their therapeutic implications?
How do ADAMTS-13 auto-antibody profiles correlate with response to plasma exchange in TTP patients?
Which biomarkers predict recurrence risk in TTP patients with ADAMTS-13 auto-antibody subtypes?
What adverse events are associated with ADAMTS-13-targeting therapies in TTP and how are they managed?
How do ADAMTS-13 auto-antibody characteristics compare to other thrombotic microangiopathy biomarkers?